当期报告
Xilio Therapeutics(XLO)03-29 04:15
$Xilio Therapeutics(XLO)$ 8-K Current report, item 8.01 Accession Number: 0001558370-24-004249 Act: 34 Size: 164 KB 网页链接
简介：Xilio Therapeutics, Inc.于2020年6月18日在特拉华州注册成立。该公司是一家生物技术公司，专注于利用免疫系统实现深度和持久的临床反应，以改善癌症患者的生活。该公司已经建立了他们的地理精确解决方案或GPS平台，以快速设计新分子，包括细胞因子和其他生物制剂，这些分子旨在通过在地理上定位肿瘤内的活动来优化其治疗指数。该公司正在通过不同的发展阶段推进一些地理上精确或肿瘤选择性的药物。该公司还计划继续利用其GPS平台开发其他免疫疗法，包括具有一系列肿瘤靶向方法的候选产品。
| 今开：1.17 | 昨收：1.18 |
| 最高：1.1827 | 最低：1.0115 |
| 涨停价： | 跌停价： |
| 总市值：41341683 |
Xilio Therapeutics(XLO)03-29 04:15
$Xilio Therapeutics(XLO)$ 8-K Current report, item 8.01 Accession Number: 0001558370-24-004249 Act: 34 Size: 164 KB 网页链接
Xilio Therapeutics(XLO)04-04 06:55
$Xilio Therapeutics(XLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-008004 Size: 7 KB 网页链接
Xilio Therapeutics(XLO)04-26 04:15
$Xilio Therapeutics(XLO)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-24-005762 Act: 34 Size: 1 MB 网页链接
Xilio Therapeutics(XLO)05-04 04:15
$Xilio Therapeutics(XLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-012150 Size: 5 KB 网页链接
Xilio Therapeutics(XLO)04-02 04:46
$Xilio Therapeutics(XLO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001558370-24-004528 Act: 34 Size: 327 KB 网页链接
Xilio Therapeutics(XLO)05-04 04:15
$Xilio Therapeutics(XLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-012151 Size: 5 KB 网页链接
Xilio Therapeutics(XLO)04-15 21:05
$Xilio Therapeutics(XLO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001558370-24-005063 Act: 33 Size: 41 KB 网页链接
Xilio Therapeutics(XLO)05-07 18:05
$Xilio Therapeutics(XLO)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001398 Act: 33 Size: 1 KB 网页链接
Xilio Therapeutics(XLO)02-15 03:15
$Xilio Therapeutics(XLO)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001213 Act: 34 Size: 89 KB 网页链接
Xilio Therapeutics(XLO)03-28 20:05
$Xilio Therapeutics(XLO)$ 8-K Current report, items 1.01, 2.02, 2.05, 3.02, 7.01, 8.01, and 9.01 Accession Number: 0001558370-24-004165 Act: 34 Size: 997 KB 网页链接
格隆汇3月28日｜药物开发商Xilio Therapeutics(XLO.US)盘前一度暴涨近三倍%，报2.5美元。消息面上，该公司宣布与吉利德签订独家许可协议，以开发和商业化其癌症疗法。根据交易条款，Xilio将获得4350万美元的预... 网页链接
$Xilio Therapeutics(XLO)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001398 Act: 33 Size: 1 KB 网页链接
$Xilio Therapeutics(XLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-012149 Size: 5 KB 网页链接
$Xilio Therapeutics(XLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-012150 Size: 5 KB 网页链接
$Xilio Therapeutics(XLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-012152 Size: 5 KB 网页链接
$Xilio Therapeutics(XLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-012151 Size: 5 KB 网页链接
$Xilio Therapeutics(XLO)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001558370-24-006287 Act: 33 Size: 320 KB 网页链接
$Xilio Therapeutics(XLO)$ ARS Annual Report to Security Holders Accession Number: 0001558370-24-005773 Act: 34 Size: 11 MB 网页链接
$Xilio Therapeutics(XLO)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-24-005762 Act: 34 Size: 1 MB 网页链接
$Xilio Therapeutics(XLO)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001558370-24-005768 Act: 34 Size: 407 KB 网页链接
$Xilio Therapeutics(XLO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001558370-24-005063 Act: 33 Size: 41 KB 网页链接